[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin, 2016, 66(1):7-30.
doi: 10.3322/caac.21332
|
[2] |
Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2):115-132.
doi: 10.3322/caac.21338
|
[3] |
Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet, 2013, 381(9864):400-412.
doi: 10.1016/S0140-6736(12)60643-6
pmid: 23374478
|
[4] |
Julien JP. Neurofilament functions in health and disease. Curr Opin Neurobiol, 1999, 9(5):554-560.
pmid: 10508735
|
[5] |
Yuan AD, Rao MV, Veeranna , Nixon RA. Neurofilaments at a glance. J Cell Sci, 2012, 125(Pt 14):3257-3263.
doi: 10.1242/jcs.104729
|
[6] |
Chen R, Masuo K, Yogo A, Yokoyama S, Sugiyama A, Seno H, Yoshizawa A, Takaishi S. SNAIL regulates gastric carcinogenesis through CCN3 and NEFL. Carcinogenesis, 2021, 42(2):190-201.
doi: 10.1093/carcin/bgaa133
pmid: 33313663
|
[7] |
Li XQ, Li L, Xiao CH, Feng YM. NEFL mRNA expression level is a prognostic factor for early-stage breast cancer patients. PLoS One, 2012, 7(2):e31146.
doi: 10.1371/journal.pone.0031146
|
[8] |
Wang ZY, Xiong J, Zhang SS, Wang JJ, Gong ZJ, Dai MH. Up-regulation of microRNA-183 promotes cell proliferation and invasion in glioma by directly targeting NEFL. Cell Mol Neurobiol, 2016, 36(8):1303-1310.
doi: 10.1007/s10571-016-0328-5
|
[9] |
Capasso M, Diskin S, Cimmino F, Acierno G, Totaro F, Petrosino G, Pezone L, Diamond M, McDaniel L, Hakonarson H, Iolascon A, Devoto M, Maris JM. Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res, 2014, 74(23):6913-6924.
doi: 10.1158/0008-5472.CAN-14-0431
pmid: 25312269
|
[10] |
Shen ZJ, Chen BS, Gan XF, Hu WC, Zhong GZ, Li HF, Xie X, Liu YQ, Li HG, Xu X, Huang ZQ, Chen J. Methylation of neurofilament light polypeptide promoter is associated with cell invasion and metastasis in NSCLC. Biochem Biophys Res Commun, 2016, 470(3):627-634.
doi: 10.1016/j.bbrc.2016.01.094
|
[11] |
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer, 2013, 13(2):97-110.
doi: 10.1038/nrc3447
pmid: 23344542
|
[12] |
Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science, 2011, 331(6024):1559-1564.
doi: 10.1126/science.1203543
|
[13] |
Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res, 2004, 10(21):7335-7346.
doi: 10.1158/1078-0432.CCR-04-0183
pmid: 15534110
|
[14] |
Lo HC, Zhang XHF. EMT in metastasis: finding the right balance. Dev Cell, 2018, 45(6):663-665.
doi: 10.1016/j.devcel.2018.05.033
|
[15] |
Liu WW, Wang XC, Wang YY, Dai YB, Xie YY, Ping Y, Yin BB, Yu P, Liu ZP, Duan XZ, Liao ZP, Chen YH, Liu CH, Li X, Tao ZH. SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing EMT. J Exp Clin Cancer Res, 2018, 37(1):73.
doi: 10.1186/s13046-018-0743-1
|
[16] |
Zhao ZL, Ma SR, Wang WM, Huang CF, Yu GT, Wu TF, Bu LL, Wang YF, Zhao YF, Zhang WF, Sun ZJ. Notch signaling induces epithelial-mesenchymal transition to promote invasion and metastasis in adenoid cystic carcinoma. Am J Transl Res, 2015, 7(1):162-174.
|
[17] |
Zhu JF, Liu Y, Huang H, Shan L, Han ZG, Liu JY, Li YL, Dong X, Zeng W. MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth. Cancer Cell Int, 2018, 18(1):193.
doi: 10.1186/s12935-018-0684-y
|
[18] |
Ceresa BP, Peterson JL. Cell and molecular biology of epidermal growth factor receptor. Int Rev Cell Mol Biol, 2014, 313:145-178.
doi: 10.1016/B978-0-12-800177-6.00005-0
pmid: 25376492
|
[19] |
Lamorte L, Park M. The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am, 2001, 10(2):271-288.
pmid: 11382587
|
[20] |
Wei QC, Chen LR, Sheng LM, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol, 2007, 31(3):493-499.
|
[21] |
Kashyap MK, Abdel-Rahman O. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Mol Cancer, 2018, 17(1):54.
doi: 10.1186/s12943-018-0790-4
pmid: 29455652
|
[22] |
Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol, 2005, 1:2005.0010.
|
[23] |
Bheda A, Creek KE, Pirisi L. Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. Oncogene, 2008, 27(31):4315-4323.
doi: 10.1038/onc.2008.65
pmid: 18391986
|
[24] |
Haley J, Whittle N, Bennet P, Kinchington D, Ullrich A, Waterfield M. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res, 1987, 1(4):375-396.
pmid: 3329716
|
[25] |
Johnson AC. Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristate 13-acetate is mediated by activator protein 2. J Biol Chem, 1996, 271(6):3033-3038.
pmid: 8621697
|
[26] |
Stratford AL, Habibi G, Astanehe A, Jiang H, Hu KJ, Park E, Shadeo A, Buys TPH, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res, 2007, 9(5):R61.
doi: 10.1186/bcr1767
pmid: 17875215
|